Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022477 · ClinicalTrials.gov registry record · Phase 2
BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00022477 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 24 participants.
The verdict
NCT00022477, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent or metastatic colorectal cancer.
Interventions
- DRUG BMS-247550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2001-09 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022477
The ClinicalTrials.gov registry entry for NCT00022477 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-247550 is the first listed.
NCT00022477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00022477 about?
NCT00022477 is a clinical study titled "BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent or metastatic colorectal cancer.
What is the current status of trial NCT00022477?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2001-09. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00022477?
The interventions under investigation include: BMS-247550 (DRUG).
Who is sponsoring clinical trial NCT00022477?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.